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Summary 48 
Background 49 
Diabetes (DM) is common among tuberculosis (TB) patients and often undiagnosed or poorly 50 
controlled. We compared point of care (POC) with laboratory glycated haemoglobin (HbA1c) tests 51 
among newly diagnosed TB patients to assess POC test accuracy, safety, and acceptability in settings 52 
where immediate access to DM services may be difficult. 53 
Methods 54 
We measured POC and accredited laboratory HbA1c (HPLC method) in 1942 TB patients aged over 18, 55 
recruited from Peru, Romania, Indonesia, and South Africa. We calculated overall agreement and 56 
individual variation (mean ± 2 standard deviations); stratified by country, age, sex, body mass index 57 
(BMI), HbA1c level and comorbidities (anaemia, human immunodeficiency virus (HIV)). We used an 58 
error grid approach to identify disagreement that could raise significant concerns.  59 
Results 60 
Overall mean POC HbA1c values were modestly greater than laboratory HbA1c by 0.14% units (95% 61 
confidence intervals 0.11 to 0.18), but there was a substantial discrepancy for those with severe 62 
anaemia (1.07% HbA1c, 95%CI 0.67 to 1.46). For 89.6% of 1942 patients, both values indicated the 63 
same DM status (no DM; HbA1c <6.5%) or had acceptable deviation (relative difference <6%). 64 
Individual agreement was variable, with POC values up to 1.84% units higher or 1.56% lower. For a 65 
minority, use of POC HbA1c alone could result in error leading to potential over-treatment (n=40, 2.1%) 66 
or under treatment (n=1, 0.05%). The remainder had moderate disagreement, less likely to influence 67 
clinical decisions. 68 
Conclusion 69 
POC HbA1c is pragmatic and sufficiently accurate to screen for hyperglycaemia and DM risk among TB 70 
patients.  71 
 72 
 73 
  74 
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Introduction 75 
Globally, there is a high prevalence of diabetes (DM) among newly diagnosed tuberculosis (TB) 76 
patients, with estimated prevalence ranging from around 5-50% in different settings[1-7]. TB-DM 77 
patients have been shown to have higher early mortality rates (death within 100 days of starting TB 78 
treatment)[8] and worse TB treatment outcomes[9, 10]. They are also likely to have poor control of 79 
their DM during TB treatment, possibly because of hypoglycaemic or hyperglycaemic effects of anti-80 
TB chemotherapy[2], potential drug interactions and stress hyperglycaemia due to TB disease itself[2]. 81 
For these reasons, it is important to diagnose DM early on in TB treatment, and to assess the adequacy 82 
of glycaemic control, but this can be logistically difficult in low and middle income countries where TB-83 
DM incidence is expected to be the highest. WHO and several countries have made recommendations 84 
to screen all TB patients for DM[11-13], but the optimal ways of achieving this in different settings 85 
have not been established[14].  86 
The gold standard test for DM diagnosis is considered to be the Oral Glucose Tolerance Test (OGTT) 87 
as it is the most sensitive test available[15, 16]. However, in practice fasting plasma glucose (FPG) and 88 
glycated haemoglobin (HbA1c) (both acceptable for diagnosis) are more often used due to their 89 
convenience[17]. Urinary glucose tests and DM risk scores are cheaper alternatives used to identify 90 
DM status but both have lower sensitivity, and are not recommended for diagnosis[18-20]. 91 
HbA1c has been used widely to monitor DM control since the 1980s[21, 22] but it was only 92 
recommended as a diagnostic test for DM in 2011 by WHO[23]. Acceptance of HbA1c as a diagnostic 93 
test was delayed due to concerns about standardisation of HbA1c methods and assays 94 
internationally[24], and quality assurance[25, 26]. WHO therefore recommends the use of HbA1c for 95 
diagnosis of DM only when strict quality assurance measures are in place[23]. Only laboratories and 96 
manufacturers aligned to the “National Glycohemoglobin Standardization Program” (NGSP) or 97 
International Federation of Clinical Chemists (IFCC) laboratory networks and reference methods[27] 98 
are accredited to diagnose DM using HbA1c. Nevertheless, the HbA1c test has very important practical 99 
advantages, particularly as there is no need for fasting. A POC HbA1c test can be performed with 100 
limited facilities and space, being based on a single finger-prick (capillary) blood sample, which is then 101 
applied to a cartridge, and inserted into a desktop analyser; HbA1c is quantified and reported within 102 
just a few minutes. Therefore, POC HbA1c test could be administered by trained health care workers 103 
instead of relying on the presence of health care professionals, which would be beneficial for settings 104 
with limited personnel resources (e.g. nurse-led centres). Due to their practical advantages POC tests 105 
are becoming more widely used in TB clinics[7, 28, 29], both to screen patients for undiagnosed DM, 106 
and to identify those with poorly controlled DM who may require further management. However, to 107 
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our knowledge DM diagnosis using POC HbA1c has not yet been recommended by WHO or any 108 
regulatory bodies, and the implications of using POC tests, compared with laboratory alternatives, 109 
have not been extensively explored, particularly not among TB patients.  110 
A recent review among DM individuals showed very high levels of agreement (correlation coefficient, 111 
0.967; 95% CI 0.960–0.973) between laboratory and POC HbA1c[30]; however, included studies mostly 112 
took place with industry involvement, or were carried out under “optimal” conditions. Another 113 
review[31] among 60 studies comparing the performance of POC devices to laboratory testing in 114 
HbA1c showed a negative mean bias in pooled results (i.e. POC HbA1c < laboratory HbA1c) although 115 
with large variabilities between devices; but studies included were not restricted to specific 116 
participants’ characteristics (e.g. people with or without co-morbidities). In this article, we explored 117 
the agreement between POC and laboratory HbA1c results among TB patients from four middle 118 
income countries[32]. We also assessed the field worker’s perceptions of the ease of use and 119 
acceptability of each test, adapting a protocol previously set out for this purpose[33].  120 
Method  121 
Study overview and population 122 
The TANDEM study was a multi-centred international study designed to identify optimal ways to 123 
screen and manage DM in TB patients[32]. Baseline screening was conducted between 2013 and 2017 124 
in four countries: Indonesia, Peru, South Africa, and Romania. Participants aged 18 years or older were 125 
included if they were recruited within 72 hours of pulmonary TB treatment initiation. We included 126 
either newly diagnosed or previously treated cases, regardless of their HIV status. Appendices 1-2 127 
showed further details of the sites and recruitment methods. For this study we included individuals 128 
with both a laboratory and POC HbA1c result regardless their DM status at the time of testing.  129 
Measurements  130 
POC HbA1c (analysed using Hemocue® HbA1c 501 Analyser)[34] was collected during the participants’ 131 
clinic visits, and within 72 hours after TB diagnosis. In Romania, HemoCue® was not available so the 132 
QuoTest[35] HbA1c Analyser QTD (by EKF Diagnostics) was substituted for Hemocue®. Laboratory 133 
HbA1c was estimated from venous blood sample collection taken at the same time as the POC test. 134 
All laboratory HbA1c samples were analysed using the HPLC method as per WHO guidelines and were 135 
carried out in an accredited laboratory with NGSP certification[36]. 136 
Consent and ethical approval  137 
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All patients gave written informed consent. The study was approved by the Research Ethics 138 
Committee, London School of Hygiene & Tropical Medicine (LSHTM ethics ref: 6449, LSHTM 139 
amendment no: A473). Ethical permissions were also received from relevant local and/or national 140 
research committees.  141 
Analyses  142 
We compared the mean and 95% Confidence Intervals (CI) for HbA1c from POC and laboratory sources 143 
in the whole sample using paired t tests. We further explored the mean differences in subgroups 144 
stratifying by variables that could potentially affect HbA1c level, these variables include country 145 
(Indonesia, Peru, South Africa, and Romania), age group (<30 years, 30-39 years, 40-49 years, 50-59 146 
years, and ≥60 years), sex (male or female), BMI (<18.5 kg/m2, 18.5-24.9 kg/m2, 25.0-29.9 kg/m2, ≥30.0 147 
kg/m2)[37], anaemia (non-anaemia, mild anaemia, moderate anaemia, and severe anaemia, based on 148 
standard WHO definitions for men and women separately)[38], and HIV status (HIV positive or 149 
negative). We calculated robust standard errors to account for the clustering of data within four 150 
countries in our study. We also compared POC and laboratory HbA1c levels within different laboratory 151 
HbA1c ranges to explore whether the agreement between the two measures varied between specific 152 
HbA1c ranges (<5.7%, 5.7-6.4%, 6.5-8.9%, ≥9%). These ranges were chosen based on American 153 
Diabetes Association criteria[39]; they defined “pre-diabetes” as an HbA1c measurement between 154 
5.70% and 6.49%). The cut-point of 9% for severe uncontrolled DM was based on the upcoming WHO 155 
guidelines and on previous research[40]. The intra-individual differences (mean ± 2 standard 156 
deviations i.e. range of agreement within which 95% of patients fall) were also calculated across 157 
subgroups, and Bland-Altman plots of agreement were produced for the whole sample and for all 158 
subgroups. We explored whether any key covariates (age group, sex, country, BMI level, laboratory 159 
HbA1c level, anaemia, and HIV status) could explain individual differences between the POC and 160 
laboratory values by running linear regression models with the unit difference between the two tests 161 
as the outcome, separately for each covariate. We also examined the overall differences across all 162 
levels for each covariate with over two categories using Wald test. Statistical analyses were performed 163 
using STATA version 12.0[41]. 164 
A priori, we determined that an acceptable level of agreement would be one that resulted in the same 165 
categorisation (DM, yes or no) and / or had a relative difference of less than 6%, chosen based on 166 
NGSP criteria of acceptable performance limits for manufacturers’ methods[42]. An “error grid” was 167 
completed to assess the clinical relevance of findings, taking into account that the clinical importance 168 
of any particular difference in HbA1c, depends on the absolute levels of both values, and not simply 169 
the percentage or absolute difference[40, 43, 44]. We explored agreement across the standard 170 
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diagnostic cut-point (6.5%), and also at a threshold previously used for “severe uncontrolled” DM 171 
(9%)[40].  172 
To assess the operational feasibility of implementing the tests in settings where TB patients were 173 
being treated, structured questionnaires were administered to nine health care workers performing 174 
the POC test and collecting blood for the laboratory HbA1c tests in Indonesia (n=5), Peru (n=3) and 175 
South Africa (n=1) at the start and end of the study. The tests were assessed for user-friendliness, self-176 
reported training and performance time, acceptability by health care workers, perceived patient 177 
acceptability (possible reasons for non-compliance or unwillingness to have tests performed), sample 178 
and equipment quality, logistics of performing tests and reporting results, and perceived 179 
appropriateness. These domains were derived by adapting and expanding a previously developed 180 
scale that evaluated the characteristics of manual haemoglobin techniques alongside a reference 181 
method in Malawi[33]. The questionnaires were delivered by face to face interview with health care 182 
workers in all study countries[33]. 183 
Response options included a five-point Likert scale (strongly agree to strongly disagree) for user 184 
friendliness and several other approaches for all the domains. These included open-ended responses 185 
as well as closed-ended categorical options for agreement (yes/no), or frequency (never/only when 186 
outside normal range, always), and completing numeric values for predetermined units of quantity 187 
and time. Participant responses were entered into Excel (Microsoft Corporation, Redwood, WA, USA), 188 
where proportions and measures of central tendency were calculated for quantitative data. Thematic 189 
analysis was performed for open text responses by creating codes for the text. The coded text was 190 
arranged into categories, which were them used to generate themes that were incorporated into the 191 
existing domains. No internal consistency of questions was performed. All health care workers 192 
performing the DM tests in the TANDEM study were approached to participate in the operational 193 
feasibility study. At the start of the study all 14 health care workers participated, but at the end of the 194 
study the questionnaires were only administered to nine health care workers (64% response) due to 195 
some staff having already moved to other jobs. 196 
Results  197 
Out of 2345 TB patients, 1942 (734 from Indonesia, 542 from Peru, 416 from Romania, and 250 from 198 
South Africa) had both a baseline POC and laboratory HbA1c result available (see Table 1). A total of 199 
157 patients had no POC test, mainly because of temporary equipment failure or shortage of 200 
cartridges affecting particularly one remote, rural site in Romania. Only 72 people (4.2%) were HIV 201 
positive, though 97 patients refused HIV testing , 91 did not have the test done, three had confirmed 202 
laboratory results missing, 17 did not have test done for unclear reasons, and further ten people had 203 
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laboratory results missing but for no known reason. The median age was 35 years, 61% of the study 204 
sample were men, 37% were underweight and 9% were overweight or obese. Almost half of the 205 
participants had anaemia of some extent: 29% with mild anaemia, 18% with moderate anaemia, and 206 
1.4% with severe anaemia.  207 
Mean agreement (population agreement) 208 
Table 1 shows the baseline mean HbA1c results from POC and laboratory sources. In the total sample, 209 
POC HbA1c results were significantly greater than laboratory HbA1c level by 0.14% units (95%CI 0.11 210 
to 0.18). We did not identify substantial differences in population level mean HbA1c by age group, sex, 211 
or BMI level.  212 
POC HbA1c levels were higher than laboratory HbA1c results in patients with anaemia, and the largest 213 
difference was found among those with severe anaemia (1.07% (95%CI 0.67% to 1.46%) P=0.001) (see 214 
Table 2). POC HbA1c results were higher than laboratory values regardless of HIV status, although the 215 
difference was not significant amongst HIV negative (0.15% (0.11%, 0.19%)) compared to positive 216 
patients (0.30% (0.10%, 0.49%)). There was a small but significant difference in HbA1c results by 217 
country: POC HbA1c was found to be slightly higher than laboratory HbA1c in Indonesia (0.26% (95%CI 218 
0.21 to 0.31)) and Peru (0.55% (95%CI 0.47 to 0.64)), but slightly lower in Romania -0.37% (95%CI -219 
0.42 to -0.31) and South Africa (-0.23% (95%CI -0.32% to -0.13%). The difference in direction could 220 
reflect significantly higher mean POC HbA1c in Peru and Indonesia (6.1 and 6.2% HbA1c), compared 221 
with Romania and South Africa (both 5.6%). The greatest mean difference was found in Peru, where 222 
a batch of the POC test was subsequently manufacturer identified as inaccurate. In a sensitivity 223 
analysis, we removed values for the period of time in which this substandard batch were used 224 
(affecting 184 out of 542, 39% of tests in Peru), but this did not substantially alter the mean difference 225 
in Peru (0.59% (95%CI 0.48% to 0.69%, compared to 0.55% (95%CI 0.47 to 0.64) when including the 226 
faulty batch). The mean difference between POC and HbA1c increased with higher laboratory HbA1c 227 
level.  228 
Individual variation in agreement 229 
Overall, the mean ± 2 standard deviations for within individual agreement ranged from +1.84 to – 1.56% 230 
HbA1c, suggesting that individual TB patients could have a difference of up to nearly 2 units of HbA1c% 231 
higher or 1.5 units lower on the POC test (i.e. a POC measurement of 6.5% could be in the range 5.0% 232 
- 7.9% on the laboratory test) (see Table 2). Intra-individual differences were similar for most sub-233 
groups but appeared widest for those with severe anaemia (-0.93 to +3.06 HbA1c %), though only a 234 
small number of individuals were included in this category (n=27). There were generally smaller but 235 
statistically significant differences in the unit discrepancy between the two tests for other covariates 236 
9 
 
including age and level of laboratory HbA1c (Table 2), and Bland-Altman plots of agreement were 237 
shown in Appendix 3 for each covariate. The POC test was on average higher than the laboratory test 238 
at low levels (HbA1c < 5.7%), but this reversed and became more variable (greater intra-individual 239 
differences) at higher levels of HbA1c.  240 
Error grid analysis (see Figure 1 and Table 3) 241 
For the majority of individuals their POC and laboratory HbA1c value were either both below 6.5% 242 
(n=1574, 81.1%) or only deviated from one another by less than 6% (relative difference) (n=86, 4.4%). 243 
A small number of patients (n=79; 4.1%) had greater than 6% relative deviation, but would still be 244 
assigned a concordant DM status using the standard diagnostic cut-points. Thus for 1739 patients 245 
(89.5%) there was no important difference between the two tests (see Zones A and B in Table 3 and 246 
Figure 1).  247 
However, for 10.5% of individuals, POC and laboratory HbA1c values indicated differences in DM 248 
control status. N=1 (0.1%) had a POC HbA1c estimate greater than 9% when the laboratory HbA1c 249 
estimate was between 6.5% and 8.9%; the POC suggesting severe hyperglycaemia when the 250 
laboratory test suggested more moderate hyperglycaemia (Zone C1 in Figure 1). For n=188 (9.7%) TB 251 
patients the POC value was between 6.5% and 9% when the laboratory value was <6.5%; suggesting 252 
moderate to high levels of hyperglycaemia when this was not present on the laboratory measurement 253 
(Zone D1). This could also result in possible over-treatment, most likely to arise for the lower 254 
proportion (n=28, 1.4%) of patients with POC ≥8%, whilst the laboratory test was <6.5%. For 0.6% of 255 
individuals (n=11) the POC HbA1c was > 9% when the laboratory HbA1c was less than 6.5%, leading to 256 
a substantial risk of over-treatment (Zone E1). Overall, 40 patients (1 in Zone C1, 28 in Zone D1, and 257 
11 in Zone E1, 2.1%) could risk unnecessary treatment or referral based on the POC test result. Only 258 
one individual (0.05%) had a POC <6.5% when the laboratory HbA1c was >9.0% and could thus be 259 
incorrectly classified as below this threshold when they had very severe hyperglycaemia.  260 
Operational feasibility 261 
At both time points for the operational feasibility study the POC was assessed by health care workers 262 
as more user friendly than the laboratory HbA1c, particularly because of the direct and rapid result. 263 
In terms of perceived appropriateness of tests, health care workers were initially hesitant about 264 
adopting a new test and on average their self-assessment for training time was that it took them four 265 
and a half working days (range of 30 minutes to seven working days) to feel that they could proficiently 266 
perform the POC test, but by the end of the study their perception was that less time (only one and a 267 
half working days; range 30 minutes to three working days) was needed, having performed the test 268 
consistently for an average of two years during the TANDEM study. After two years’ experience, the 269 
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average time estimated to perform a POC test (6.4 minutes) was slightly more than the time estimate 270 
to perform the blood draw for the laboratory HbA1c (4.5 minutes). The POC test was generally 271 
perceived to be more acceptable by patients than a venous blood draw, though 13% of respondents 272 
indicated that some patients were unwilling to have their fingers pricked. The quality of the POC 273 
machines was also a concern for the health care workers, as whilst they did not break down often, the 274 
down time when a repair was needed was perceived to increase from 12 to 16 hours after two years. 275 
However, this corresponded with a decrease in the daily quality control checks of the machines from 276 
64% to 38%, demonstrating potential reduced equipment maintenance over time as the test became 277 
more familiar.  278 
Discussion 279 
Overall, the vast majority of patients (89.6%) were classified by both tests as having the same DM 280 
status or the differences were within an acceptable margin of error. Mean differences were also very 281 
small for most patients (except for those with severe anaemia), suggesting that the POC test can be 282 
used to monitor DM prevalence at a population level. It is well-known that anaemia can affect HbA1c 283 
level; a recent systematic review[45] suggested that HbA1c can be over-estimated in the presence of 284 
iron deficiency anaemia, and may be under-estimated in the presence of other forms of anaemia. We 285 
had previously analysed the relationship between laboratory HbA1c and anaemia in our study, and 286 
found no overall statistically significant difference in HbA1c across anaemia categories (especially 287 
among non-, mild-, and moderate anaemia) on HbA1c levels in TANDEM study, although for those 288 
patients with severe anaemia HbA1c did appear lower[14]. Another Indian study among TB patients 289 
recently showed little difference in HbA1c by level of anaemia[4]. Nevertheless, our data suggests that 290 
it might not be appropriate to use HbA1c for screening in TB patients with severe anaemia, but due to 291 
the small sample size we could not analyse this further.  292 
Despite good mean (population level) agreement for most patients, at an individual level there were 293 
substantial differences between laboratory and POC HbA1c, with POC HbA1c ranging from almost 2 294 
units higher to about 1.5 units lower than laboratory HbA1c values. For just under 2.5%, the POC test 295 
substantially over-estimated the laboratory test in a clinically important range. However, clear 296 
guidance to TB clinics to repeat POC HbA1c tests for those with severely raised initial levels (≥8%) but 297 
no previously known DM, or to use an alternative fasting glucose test, should help mitigate against 298 
this risk. In our study this would have resulted in 70 repeated tests (<5%). After the initial stages of 299 
treatment when the patient is no longer infectious, it may be appropriate to refer to DM services. For 300 
more severe, uncontrolled DM, specialist advice should be sought including the need for hospital 301 
admission, particularly if HbA1c is over 10%. For those with moderate hyperglycaemia, specialist 302 
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advice should also be sought including intensifying glucose treatment, monitoring, and management. 303 
Local expertise, availability of DM medications and monitoring, will all determine the precise 304 
thresholds at which urgent referral or advice might be required. Specific guidance on management 305 
targets for DM among TB patients aimed at front line health care workers is currently under review 306 
and expected to be published by the International Union Against Lung Disease later this year. We also 307 
suggest that all patients potentially newly identified with DM should be followed up towards the end 308 
of TB treatment and referred to DM services where appropriate, and this guidance should prevent 309 
over-diagnosis and treatment in the longer term.  310 
The strength of our study is the relatively large number of patients with both laboratory and POC 311 
HbA1c test results from four continents. Our analyses also addresses a pressing need, since following 312 
initiatives to support screening for DM in TB patients[11, 12, 46, 47], capillary POC tests are being 313 
introduced in TB clinics. In our study, the tests were performed at the same time during the initial 314 
clinic visit. We also used field-based rather than laboratory trained staff, and assessed patient/field 315 
worker satisfaction of use of POC. Our results are thus more likely to reflect potential agreement in 316 
practice, compared with manufacturer or laboratory based studies which often use highly skilled 317 
testers in near optimal conditions. Laboratory measurements of HbA1c were all performed in 318 
accredited laboratories, certified to NGSP standards. Missing data were very low for most covariates 319 
and tests, except in one remote site where some POC HbA1c tests had not been taken. Overall, 93% 320 
of eligible patients had the POC test performed. We also used an error grid approach to explore the 321 
agreement in key clinical areas where treatment or referral decisions might be made, rather than 322 
simply calculating diagnostic accuracy at a set cut-point. The key limitations are some missing data for 323 
HIV status, and the use of a different POC test in Romania, where Hemocue® was not available. The 324 
overall pattern of results in Romania is, however, consistent with the other countries included. We 325 
found quality control problems with the POC HbA1c cartridges, clearly affecting some tests. This would 326 
likely not have been identified outside of a research setting, in which we were using other DM tests 327 
simultaneously. After noticing the discrepancy at an early stage in one site (Lima, Peru) we approached 328 
the manufacturer for advice, but retained the apparently inaccurate POC batch values in our main 329 
analyses, as this reflects what would be most likely to happen in practice.  330 
Other studies comparing POC and laboratory HbA1c values among TB patients are rare. A study 331 
amongst 400 adults with suspected TB reported poor agreement between POC and laboratory HbA1c 332 
results in Nigeria[48]. Their POC for HbA1c showed low sensitivity (50%) and moderate specificity 333 
(74.5%) compared with the laboratory based HbA1c test. The study population had a high HIV 334 
prevalence and no further details of the agreement between the two tests (such as the actual 335 
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discrepancy in HbA1c estimated), or the training and experience of those undertaking the POC test 336 
were provided.  337 
The key benefit of using POC tests among TB patients is the potential for rapid diagnosis and better 338 
management to improve clinical outcomes among those with TB-DM. Overall, there was a high 339 
acceptance of POC HbA1c for use in real world settings in both remote and non-remote clinics, 340 
especially as there is no need for repeat visits or for individuals to be fasting. Field workers found the 341 
test generally acceptable to use, though the initial training time estimated, down time, and diminution 342 
in quality control checks over time stress the importance of initial training and suggest that regular re-343 
training and assessment would be required in practice. The cost of POC testing is much lower than 344 
other types of HbA1c test, due to its immediate result-reading, which would be ideal for low-middle 345 
income countries with limited resources in local primary care centres. Potentially, the cost of POC 346 
HbA1c could be reduced further by limiting its use to TB patients with an initial raised non-fasting 347 
(random) capillary glucose level, which in our study would have reduced the need for the POC test by 348 
around 70%[14]. However, the financial assistance and educational support from local government 349 
and international public health promoters (e.g. WHO, NGO) in collaboration with test manufacturers 350 
would likely still be required to facilitate the process, especially in more remote and disadvantaged 351 
communities. A recent study in South Africa suggested that POC HbA1c test significantly improved the 352 
glycaemic control in less advantaged local DM clinic and increased the accessibility for DM patients in 353 
the community[49]. POC HbA1c tests are generally thought to be stable at room temperature for many 354 
months, and some studies have found good agreement with laboratory results even in more extreme 355 
temperatures[50], but this has not been widely assessed. POC HbA1c is ideal for measuring 356 
hyperglycaemia at a population level, since mean differences with laboratory HbA1c were small. POC 357 
HbA1c provides feedback on risk of DM amongst TB patients to health care professionals and patients. 358 
It can also highlight those potentially at risk of poor TB outcome, who may need additional 359 
management. Overall, for most patients agreement with the laboratory measure was either good or 360 
would not affect clinical decisions. Patients with a significantly raised POC HbA1c (e.g. ≥8%) and 361 
without known DM could be assessed clinically including evaluating whether they have known DM risk 362 
factors (e.g. family history of DM), and offered a repeated HbA1c test or fasting blood glucose test to 363 
confirm the level of hyperglycaemia. In our population, this would have resulted in repeat testing for 364 
only 5% of patients. Ideally, those with severe anaemia (1.4% of our study) should also receive an 365 
alternative test, since POC HbA1c performed poorly in this group. Newer technologies should also be 366 
assessed in similar studies as they enter the market, but all potential pragmatic and feasible tests may 367 
suffer some limitations in terms of accuracy[51]. POC HbA1c is sufficiently accurate and likely the test 368 
of choice for screening among most TB patients at present.  369 
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Table 1 Baseline mean HbA1c (%) results from POC and lab in TANDEM study* 
Variables  N (%) Mean (95%CI) 
   POC HbA1c Lab HbA1c 
Total sample  1942 (100.00) 6.00 (5.94, 6.06) 5.85 (5.80, 5.91) 
     
Sex Female 752 (38.74) 6.06 (5.96, 6.16) 5.84 (5.74, 5.95) 
 Male 1189 (61.26) 5.96 (5.89, 6.03) 5.86 (5.80, 5.93) 
     
Age group <30yrs 701 (36.10) 5.74 (5.69, 5.79) 5.55 (5.51, 5.59) 
 30-39yrs 444 (22.86) 5.93 (5.83, 6.03) 5.66 (5.60, 5.72) 
 40-49yrs 363 (18.69) 6.05 (5.89, 6.20) 6.05 (5.88, 6.22) 
 50-59yrs 254 (13.08) 6.46 (6.21, 6.71) 6.44 (6.19, 6.69) 
 60yrs+ 180 (9.27) 6.44 (6.17, 6.71) 6.31 (6.07, 6.56) 
     
BMI† Underweight 714 (36.88) 5.89 (5.82, 5.97) 5.77 (5.70, 5.84) 
 Normal range 1055 (54.49) 5.99 (5.91, 6.08) 5.85 (5.77, 5.93) 
 Overweight 142 (7.33) 6.42 (6.14, 6.70) 6.17 (5.87, 6.47) 
 Obese 25 (1.29) 6.91 (5.97, 7.85) 6.75 (5.77, 7.73) 
     
Country Indonesia 734 (37.80) 6.23 (6.11, 6.35) 5.96 (5.84, 6.08) 
 Peru 542 (27.91) 6.14 (6.03, 6.24) 5.59 (5.51, 5.66) 
 Romania 416 (21.42) 5.62 (5.54, 5.70) 5.99 (5.90, 6.08) 
 South Africa 250 (12.87) 5.64 (5.53, 5.75) 5.87 (5.77, 5.96) 
     
Anaemia‡ Non-anaemia 1003 (51.67) 5.96 (5.87, 6.05) 5.85 (5.76, 5.93) 
 Mild anaemia 557 (28.70) 6.03 (5.92, 6.13) 5.92 (5.82, 6.02) 
 Moderate anaemia 354 (18.24) 6.02 (5.91, 6.14) 5.82 (5.71, 5.93) 
 Severe anaemia 27 (1.39) 6.39 (6.02, 6.76) 5.32 (5.11, 5.54) 
     
Lab HbA1c <5.7 1123 (57.83) 5.71 (5.66, 5.76) 5.34 (5.32, 5.36) 
 5.7-6.4 659 (33.93) 5.91 (5.86, 5.95) 6.01 (6.00, 6.02) 
 6.5-8.9 99 (5.10) 6.31 (6.12, 6.51) 6.91 (6.79, 7.02) 
 9+ 61 (3.14) 11.81 (11.35, 12.28) 11.95 (11.44, 12.46) 
     
HIV status HIV- 1654 (95.82) 6.03 (5.96, 6.09) 5.88 (5.81, 5.94) 
 HIV+ 72 (4.18) 5.95 (5.74, 6.16) 5.66 (5.49, 5.82) 
* Participant numbers reported here vary slightly from some other TANDEM consortium analyses owing to minor differences in inclusion criteria and/or 
recruitment period 
† Underweight: <18.5 kg/m2; normal range: 18.5-24.9 kg/m2; overweight: 25.0-29.9 kg/m2; obese: ≥30.0 kg/m2. 
‡ Anaemia categories were defined according to WHO. Among non-pregnant women (>15 years) non-anaemia defined as haemoglobin levels >120g/L, mild 
anaemia defined as 110-119g/L,  moderate anaemia was defined as 80-109g/L, and severe anaemia was defined as <80g/L; among men, non-anaemia defined 
as >130g/L, mild anaemia was defined as 110-129g/L, moderate anaemia defined as 80-109g/L, and severe anaemia defined as <80g/L. Among women, there 
were five people pregnant and their anaemia level was defined differently as below: non-anaemia >110g/L, mild anaemia is 100-109g/L, moderate anaemia is 
70-99g/L, and severe anaemia is <70g/L.    
 
 
 
 
 
 
 
 
 
 
                                                          
 Table 2 Intra-individual difference for HbA1c from POC and laboratory sources stratified covariates 
Variables  Mean 
Intra-individual difference 
(POC-Lab) 
mean-2SD, mean+2SD 
P value 
Total sample  0.14 -1.56, 1.84 <0.001 
     
Sex Female 0.21 -1.48, 1.90 Ref  
 Male 0.10 -1.60, 1.80 0.136 
     
Age group§ <30yrs 0.19 -1.36, 1.73 Ref 
 30-39yrs 0.27 -1.79, 2.33 0.340 
 40-49yrs -0.001 -1.54, 1.54 0.017 
 50-59yrs 0.02 -1.39, 1.43 0.010 
 60yrs+ 0.13 -1.71, 1.97 0.704 
     
BMI** Underweight 0.12 -1.33, 1.58 Ref 
 Normal range 0.14 -1.70, 1.98 0.931 
 Overweight 0.25 -1.54, 2.04 0.566 
 Obese 0.16 -1.03, 1.34 0.846 
     
Country Indonesia 0.26 -1.10, 1.62 Ref 
 Peru 0.55 -1.48, 2.58 <0.001 
 Romania -0.37 -1.47, 0.74 <0.001 
 South Africa -0.23 -1.70, 1.25 <0.001 
     
Anaemia†† Non-anaemia 0.12 -1.58, 1.82 Ref 
 Mild anaemia 0.11 -1.55, 1.78 0.920 
 Moderate anaemia 0.20 -1.45, 1.85 0.523 
 Severe anaemia 1.07 -0.93, 3.06 0.038 
     
Lab HbA1c <5.7 0.37 -1.33, 2.07 Ref 
 5.7-6.4 -0.11 -1.32, 1.11 0.014 
 6.5-8.9 -0.60 -2.16, 0.97 0.011 
 9+ -0.13 -3.09, 2.82 0.020 
     
HIV status HIV- 0.15 -1.43, 1.73 Ref 
 HIV+ 0.30 -1.34, 1.93 0.940 
§ Wald test was used to test overall differences across all categories; P>0.100 for all tested variables except for country (P<0.001) and Lab 
HbA1c groups (P=0.035). 
** Underweight: <18.5 kg/m2; normal range: 18.5-24.9 kg/m2; overweight: 25.0-29.9 kg/m2; obese: ≥30.0 kg/m2. 
†† Anaemia categories were defined according to WHO. Among non-pregnant women (>15 years) non-anaemia defined as haemoglobin 
levels >120g/L, mild anaemia defined as 110-119g/L,  moderate anaemia was defined as 80-109g/L, and severe anaemia was defined as 
<80g/L; among men, non-anaemia defined as >130g/L, mild anaemia was defined as 110-129g/L, moderate anaemia defined as 80-109g/L, and 
severe anaemia defined as <80g/L. Among women, there were five people pregnant and their anaemia level was defined differently as below: 
non-anaemia >110g/L, mild anaemia is 100-109g/L, moderate anaemia is 70-99g/L, and severe anaemia is <70g/L.    
 
 
 
 
 
 
 
 
 
 
 
                                                          
 Table 3 Error grid analysis zones and clinical interpretation 
Zone # Definition  Comparison with 
reference standard  
N (%) Clinical 
interpretation 
A  POC<6.5 & Lab<6.5 
Or  
Lab-6%<POC< Lab+6% 
POC deviates from 
reference by ≤6% or 
both values are <6.5 
1660 (85.5) 
(1574 HbA1c<6.5 
in both POC and 
Lab results;  
86 POC values 
deviates from 
Lab results by 
less than 6%) 
 
A: POC and reference 
value both <6.5, or 
POC values deviates 
from reference 
values by ≤6% 
 
 
B1 POC> Lab+6%  
 
POC deviates from 
reference by >6% 
 
 
12 (0.6) B1 and B2: POC 
deviates from 
reference by >6%, 
but would lead to no 
treatment or no 
erroneous treatment 
i.e. does not cross 
diagnostic cut-points 
 
B2 POC< Lab-6% POC deviates from 
reference by >6% 
67 (3.5) 
C1 POC≥9* and 
Lab≥6.5 
Overestimation  1 (0.1) C1: poor glycaemic 
control was identified 
instead of moderate 
control 
 
C2 POC<6.5 and 
8<Lab<9 
Underestimation  2 (0.1) C2: tight glycaemic 
control was identified 
instead of moderate 
control 
 
D1 6.5≤POC<9 and  
Lab<6.5 
Overestimation  188 (9.7) D1: moderate 
glycaemic control 
was identified instead 
of normoglycaemia 
 
D2 6.5≤POC<9 and 
Lab≥13 
Underestimation  0 (0) D2: moderate 
glycaemic control 
was identified instead 
of tight glycaemic 
control 
 
E1 POC≥9 and  
Lab<6.5 
Overestimation  11 (0.6) E1 poor glycaemic 
control was identified 
instead of 
normoglycaemia  
E2 POC<6.5 and 
Lab≥9 
Underestimation  1 (0.05) E2 normoglycaemia 
was identified instead 
of poor glycaemic 
control 
 
Total    1942 (100)  
 
*the stringent cut off of 9% is used as an indicator for poor control. This is based on the level of hyperglycaemia at 
which TB outcomes are thought to worsen 
# See Figure 1 below for graphical representation of the Zones.  
  
 
 
Figure 1. Error grid demonstrating agreement between the laboratory and POC HbA1c measurement 
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Appendix 1 Site locations for TANDEM study 
 
Summary - Study site locations 
In Bandung, Indonesia, suspected TB patients were recruited in 44 community health centres (CHCs) 
and from a district and a referral hospital. In Lima, Peru, patients were recruited at three primary 
health facilities and one secondary level hospital. In Romania, patients with TB were recruited from 
two secondary level hospitals, in two counties (Gorj and Dolj). In South Africa, patients were recruited 
at six community health care clinics in the northern Cape Town metropolitan area. 
Country and site selection 
For the TANDEM study, it was important to select countries from different geographic regions so that 
diverse cultural, health system structures and population demographics could be represented. The 
burden of TB and DM also needed to be sufficiently high so that there would be sufficient TB-DM 
burden within the populations to be able to detect a causal effect. The countries also needed to be 
typical of settings where economic improvement and changes in lifestyles would be likely to increase 
the risk of DM substantially. During the TANDEM proposal development in 2011, current data 
indicated that Peru and Romania had some of the highest TB incidence rates in the South American 
and European regions respectively (106 and 159 per 100,000 population respectively) and an expected 
increase of DM between 90% and 160% (WHO, 2010a). With a TB incidence of 189 per 100,000 
population (WHO, 2010a), Indonesia’s burden was well above the recommended screening threshold 
for TB in people with DM of 100 per 100,000, as recommended by the WHO/Union Framework (The 
Union and WHO, 2011), even though it was not one of the highest in the South-East Asia region at that 
time. 
The feasibility of conducting the studies was also an important criterion in the country selection and 
this was largely informed by long-term pre-existing research relationships between the TANDEM 
project principal investigators and research institutions within the countries as well as the 
collaborators’ capacity to recruit, test and treat patients for TB and DM and their access to potential 
participants. Given these considerations, Indonesia, Peru, Romania, and South Africa each with a high 
burden of TB and an increasing prevalence of DM, were selected.  
The research team based in the Universitas Padjadjaran (UNPAD) in Bandung, Indonesia has a pre-
existing research relationship with the main public tertiary teaching Hospital (RSHS), thus the DOTS 
and Endocrinology clinics at RSHS were selected for recruitment of people with TB and DM, 
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respectively. The CHCs with the greatest number of patients with TB in Bandung were contacted and 
asked to participate in the TANDEM study, with the permission and endorsement of the City Health 
Office. Patients with TB were recruited from those facilities along with the 14 additional satellite CHCs. 
Recruitment of patients with TB was lower than expected, particularly from CHCs in the east. 
Therefore, the second hospital, Ujung Berung District Hospital, was later added so that patients with 
suspected TB at CHCs in east Bandung could be sent to Ujung Berung hospital for confirmation and 
enrolment in TANDEM. 
In Peru, TANDEM made a request to the Ministry of Health to get permission and access to health 
facilities in Lima to conduct the studies in WP1 and WP2. The Ministry of Health then provided a list 
of facilities with sufficient patient volume to meet the Peru recruitment targets and that were not 
already involved in another research project, conducted by any other local or international institution. 
HAMA, the reference hospital for almost one million people in South Lima, was chosen for recruitment 
of people with DM since the Endocrinology Department and the daily DM clinic are the most accessed 
DM services in the area, particularly by uninsured people with DM. To recruit people with TB, four 
health facilities with a high or medium prevalence of TB in the Metropolitan area of Lima were chosen. 
In Romania, sites were also purposively selected based on pre-existing research collaborations with 
the country principal investigator in Dolj and Gorj counties as well as a high volume of patients with 
TB at the Victor Babes Hospital and the Runcu Hospital, and patients with DM at the two general 
hospitals. 
In South Africa, all clinical sites used for recruitment were located in the northern part of the Cape 
Town metropolitan area.  The facilities were selected because they are relatively close to 
Stellenbosch University's Faculty of Medicine and Health Sciences and cater for people with low- to 
lower-middle income for whom interventions are most needed. The areas have previously been 
reported to have a high prevalence of TB and diabetes, and the study team have a longstanding 
relationship with the personnel due to previous research activities. Diabetes patients were recruited 
from 3 Community Health Centres, under the management of Western Cape Provincial Health 
Department. Tuberculosis patients were recruited from 6 Primary Health Centres, under the 
management of City of Cape Town Health Department.  
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TANDEM – GLOBAL LOCATIONS (See tandem-fp7.eu) 
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TANDEM - SITES IN BANDUNG, INDONESIA 
 
 
  
6 
 
TANDEM - SITES IN LIMA, PERU 
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TANDEM – SITES IN CRAIOVA ROMANIA 
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TANDEM - SITES IN STELLENBOSCH, SOUTH AFRICA  
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Appendix 2 TANDEM TB diagnosis algorithm 
 
Case Definition Criteria 
Definite TB 
 
Culture or GeneXpert 
positive  
With or without: 
Suggestive TB on X-ray  
Possible TB on X-ray  
TB symptoms 
Probable TB 
 
Smear Positive  And either: 
Suggestive TB on X-ray 
Possible TB on X-ray and TB Symptoms 
Possible TB 
 
Smear Positive 
 
And either: 
Possible TB on X-ray 
TB symptoms 
TB Symptoms  And either: 
Suggestive TB on X-ray  
Possible TB on X-ray 
No TB Does not fulfil any of the above criteria 
 
 
In Indonesia and Peru, in order to obtain a positive result using the microscopic observation drug 
susceptibility assay (MODS) two colony forming units must be observed. Negative results require no 
growth. Indeterminate results occur when only one colony forming unit is observed, but is insufficient 
for bacterial confirmation. Indeterminate results are ignored by the case definition algorithm and are 
by default treated as negative1. 
 
 
1 Moore DA, Mendoza D, et al. Microscopic observation drug susceptibility assay, a rapid, reliable diagnostic test 
for multidrug-resistant tuberculosis suitable for use in resource-poor settings. J Clin Microbiol. 2004;42:4432–
4437. 
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 Appendix 3. Figures showing individual agreement between POC and 
laboratory HbA1c in the TANDEM study  
 
 
 
 
 
 
Total sample HbA1c difference 
POC was 0.14% (95%: 0.11, 0.18) greater than lab values (P<0.001) 
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By study country:  
 
 
Among Indonesian sample  
POC was 0.26% (95%: 0.21, 0.31) greater than lab values (P<0.001) 
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Among Peruvian sample 
POC was 0.55% (95%: 0.47, 0.64) greater than lab values (P<0.001) 
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Among Romanian sample 
Lab HbA1c was -0.37% (95%: -0.42, -0.31) greater than POC values (P<0.001) 
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Among South African sample 
Lab HbA1c was -0.23% (95%: -0.32, -0.13) greater than POC values (P<0.001) 
 
By sex:  
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Among women only  
POC value was statistically greater than lab values by 0.21 (95%CI: 0.15, 0.27) 
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Among men only  
POC value was statistically greater than lab values by 0.10 (95%CI: 0.05, 0.15) 
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By BMI groups:  
 
Among underweight group only 
POC values were significantly greater than lab values by 0.12 (0.07, 0.18) 
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Among normal weight group  
POC values were significantly greater than lab values by 0.14 (0.09, 0.20) 
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Among overweight group (143 people) 
POC values were significantly greater than lab values by 0.25 (0.10, 0.40) 
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Among obese group (25 people) 
There is no statistical difference between POC and lab values 0.16 (-0.09, 0.40) 
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By age groups:  
 
Among <30 years  
POC values were significantly greater than lab values by 0.19 (0.13, 0.24) 
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Among 30-39 years 
POC values were significantly greater than lab values by 0.27 (0.17, 0.36) 
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Among 40-49 years (375 people) 
There is no statistical difference between POC and lab values -0.001 (-0.08, 0.08).  
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Among 50-59 years (251 people) 
There is no statistical difference between POC and lab values 0.02 (-0.07, 0.11) 
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Among >60 years (188 people) 
Borderline significant: 0.13 (-0.01, 0.27) P=0.06 
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By anaemia status:  
 
Among non-anaemic group 
POC was significantly greater than lab values by 0.12 (0.06, 0.17). 
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Among mild anaemic group 
POC values were significantly greater than the lab values by 0.11 (0.04, 0.18) 
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Among moderate anaemic group (352 people) 
POC values were significantly greater than lab values by 0.20 (0.12, 0.29) 
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Among severe anaemic group (27 people) 
POC values were significantly greater than lab values by 1.07 (0.67, 1.46), P<0.001 
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By HIV status: 
 
Among HIV- group (1652 people) 
POC values were significantly greater than lab values by 0.15 (0.11, 0.19), P<0.001 
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Among HIV+ group (72 people) 
POC values were significantly greater than lab values by 0.30 (0.10, 0.49), P=0.003 
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